NASDAQ:TRAW Traws Pharma Q3 2026 Earnings Date & Estimates $0.38 0.00 (-0.19%) Closing price 10/21/2026 04:00 PM EasternExtended Trading$0.39 +0.02 (+4.79%) As of 06:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Traws Pharma is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Traws Pharma in Q3 2026Traws Pharma is expected to post earnings of -$0.21 per share on revenue of $2.71 million. In the same quarter a year earlier Traws Pharma reported -$0.34 per share. Traws Pharma last reported on August 14, 2026, posting -$0.16 per share and beating the -$0.3350 consensus estimate. Traws Pharma has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.21Expected Revenue$2.71 millionPrior-Year EPS-$0.34Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.16 (Beat by +$0.1750)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Traws Pharma Q3 2026 Earnings FAQ When does Traws Pharma report Q3 2026 earnings? Traws Pharma (NASDAQ:TRAW) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Traws Pharma's Q3 2026 earnings call? Traws Pharma's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Traws Pharma? Analysts expect Traws Pharma to post earnings of -$0.21 per share for Q3 2026. How much revenue is Traws Pharma expected to report? The consensus revenue estimate for Traws Pharma is $2.71 million for Q3 2026. Traws Pharma Earnings HeadlinesTraws Pharma, Inc. (NASDAQ:TRAW) Stock Rated "Reduce" by Wall Street BrokeragesOctober 18, 2026 | americanbankingnews.comTraws Pharma (NASDAQ:TRAW) versus Rafael (NYSE:RFL) Critical ReviewOctober 17, 2026 | americanbankingnews.comFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 22 at 1:00 AM | Weiss Ratings (Ad)Traws Pharma shares rise after Q2 loss comes in better than expectedAugust 17, 2026 | finance.yahoo.comTraws Pharma Reports Q2 2026 Financial Results and Provides Business HighlightsAugust 14, 2026 | globenewswire.comTraws Pharma Announces New At-The-Market Offering ProgramJuly 10, 2026 | tipranks.comSee More Traws Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email. Email Address About Traws PharmaTraws Pharma (NASDAQ:TRAW) (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing medicines for viral infections and cancer. The company’s research and development programs are focused primarily on oral antiviral therapies for respiratory viruses, including influenza and COVID-19. Traws Pharma’s antiviral pipeline includes tivoxavir marboxil, an investigational treatment designed to inhibit viral replication in influenza A, along with additional antiviral candidates targeting respiratory infections. The company is also advancing narazaciclib, an investigational oral cyclin-dependent kinase inhibitor being evaluated for potential use in oncology. The company was formed following the combination of Onconova Therapeutics and Trawsfynydd Therapeutics and adopted the Traws Pharma name as it expanded its focus to include antiviral drug development. Traws Pharma is based in the United States and conducts development activities through clinical and research programs; it does not currently have an approved commercial product.View Traws Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX Earnings Launch: High Margins Fund AI AmbitionsGM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?Synchrony Aces The Quarter As Credit Fears FadeHigher Rates Are Sending Investors to These 3 Dividend KingsServiceNow Orchestrates AI's Next Act—Can Earnings Deliver?Swiping to Record Highs: Why Visa Remains a FortressDrone Stocks Have Burned Investors—Are These 4 Different? Upcoming Earnings ENI (10/23/2026)SLB (10/23/2026)American Express (10/23/2026)Infosys (10/23/2026)Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
